Engineering a Solution for Allogeneic CAR-T Rejection

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2024 Sep 12

PMID 39265578

Authors

Leila Amini

Lena Peter

Michael Schmueck-Henneresse

Affiliations

Soon will be listed here.

References

Good Z, Spiegel J, Sahaf B, Malipatlolla M, Ehlinger Z, Kurra S . Post-infusion CAR T cells identify patients resistant to CD19-CAR therapy. Nat Med. 2022; 28(9):1860-1871. PMC: 10917089. DOI: 10.1038/s41591-022-01960-7. View

Gibson T, Engels E, Clarke C, Lynch C, Weisenburger D, Morton L . Risk of diffuse large B-cell lymphoma after solid organ transplantation in the United States. Am J Hematol. 2014; 89(7):714-20. PMC: 4069221. DOI: 10.1002/ajh.23726. View

Armand P, Gannamaneni S, Kim H, Cutler C, Ho V, Koreth J . Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2008; 26(35):5767-74. PMC: 2645102. DOI: 10.1200/JCO.2008.17.7279. View

Muller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Volkl S . CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up. N Engl J Med. 2024; 390(8):687-700. DOI: 10.1056/NEJMoa2308917. View

Spasevska I, Sharma A, Steen C, Josefsson S, Blaker Y, Kolstad A . Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma. Blood Adv. 2023; 7(23):7216-7230. PMC: 10698546. DOI: 10.1182/bloodadvances.2023010158. View

Traitanon O, Mathew J, La Monica G, Xu L, Mas V, Gallon L . Differential Effects of Tacrolimus versus Sirolimus on the Proliferation, Activation and Differentiation of Human B Cells. PLoS One. 2015; 10(6):e0129658. PMC: 4472515. DOI: 10.1371/journal.pone.0129658. View

Hill J, Li D, Hay K, Green M, Cherian S, Chen X . Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2017; 131(1):121-130. PMC: 5755046. DOI: 10.1182/blood-2017-07-793760. View

Wagner D, Fritsche E, Pulsipher M, Ahmed N, Hamieh M, Hegde M . Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol. 2021; 18(6):379-393. PMC: 8923136. DOI: 10.1038/s41571-021-00476-2. View

Li X, Daniyan A, Lopez A, Purdon T, Brentjens R . Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response. Leukemia. 2020; 35(2):506-521. PMC: 7680719. DOI: 10.1038/s41375-020-0874-1. View

10.

Amini L, Wagner D, Rossler U, Zarrinrad G, Wagner L, Vollmer T . CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients. Mol Ther. 2020; 29(1):32-46. PMC: 7791012. DOI: 10.1016/j.ymthe.2020.09.011. View

11.

Li Y, An H, Shen C, Wang B, Zhang T, Hong Y . Deep phenotyping of T cell populations under long-term treatment of tacrolimus and rapamycin in patients receiving renal transplantations by mass cytometry. Clin Transl Med. 2021; 11(11):e629. PMC: 8574956. DOI: 10.1002/ctm2.629. View

12.

Bucher P, Erdmann T, Grondona P, Xu W, Schmitt A, Schurch C . Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma. Blood. 2019; 135(2):121-132. DOI: 10.1182/blood.2019001866. View

13.

Maldini C, Messana A, Bendet P, Camblin A, Musenge F, White M . Immunosuppressant therapy averts rejection of allogeneic FKBP1A-disrupted CAR-T cells. Mol Ther. 2024; 32(10):3485-3503. PMC: 11489550. DOI: 10.1016/j.ymthe.2024.06.022. View

14.

Kueberuwa G, Kalaitsidou M, Cheadle E, Hawkins R, Gilham D . CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity. Mol Ther Oncolytics. 2018; 8:41-51. PMC: 5772011. DOI: 10.1016/j.omto.2017.12.003. View

15.

Zhang Y, Fang H, Wang G, Yuan G, Dong R, Luo J . Cyclosporine A-resistant CAR-T cells mediate antitumour immunity in the presence of allogeneic cells. Nat Commun. 2023; 14(1):8491. PMC: 10733396. DOI: 10.1038/s41467-023-44176-0. View

16.

Obama K, Yamamoto H, Inoue H . Complete remission of aggressive Epstein-Barr virus-positive diffuse large B-cell lymphoma following withdrawal of tacrolimus and low-dose anticancer drugs. EJHaem. 2023; 4(4):1160-1163. PMC: 10660111. DOI: 10.1002/jha2.761. View